Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

GM-CSF for Immunomodulation Following Trauma (GIFT) Study (GIFT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Mark Hall, Nationwide Children's Hospital
National Institute of General Medical Sciences (NIGMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Mark Hall, Nationwide Children's Hospital Identifier:
First received: December 13, 2011
Last updated: May 4, 2016
Last verified: May 2016
The GIFT study is a prospective, multi-center, interventional trial using the drug GM-CSF for the reversal of innate immune suppression in critically injured children. The study will be conducted in two phases, a dose-finding phase then an efficacy phase. The dose-finding phase is the current active phase of the study. The central hypothesis of the study is that immunomodulation with GM-CSF will result in reduction in the risk of nosocomial infection after critical injury in high-risk children through safe, rapid, and sustained improvement in innate immune function.

Condition Intervention Phase
Critical Injury (Trauma) in Children
Drug: GM-CSF
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: GM-CSF for Immunomodulation Following Trauma (GIFT) Study

Resource links provided by NLM:

Further study details as provided by Mark Hall, Nationwide Children's Hospital:

Primary Outcome Measures:
  • Immune function [ Time Frame: 7-days post-trauma ]
    To identify the lowest immunostimulatory yet tolerable dose of GM-CSF that produces lasting improvement in innate immune function in treated children.

Secondary Outcome Measures:
  • Nosocomial infection [ Time Frame: 28-days post-trauma ]

Estimated Enrollment: 200
Study Start Date: December 2011
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GM-CSF
GM-CSF is given for three days at a dose of 30, 62, or 125 mcg/m2/day to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
Drug: GM-CSF
GM-CSF is to be administered IV for three days at a dose of 30, 62, or 125 mcg/m2 per day if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
Other Names:
  • sargramostim
  • leukine

Detailed Description:
The current phase of the study is an open-label dose-finding phase in which critically injured children undergo prospective, serial immune function testing in the first few days after injury. If a subject's immune function (as measured by whole blood ex vivo LPS-induced TNF-alpha production capacity) is below a critical threshold, the subject will receive GM-CSF at a dose of 30, 62, or 125 mcg/m2 per day for three days. Enrollment is stratified by pubertal status (Tanner 1 or Tanner > 1) and by presence or absence of severe traumatic brain injury (TBI). Dose-finding is being conducted independently in each of these strata. The outcome variable for the dose-finding phase of the GIFT study is restoration of TNF-alpha production capacity and monocyte HLA-DR expression by the end of treatment, persisting to post-trauma day 7. A subsequent randomized, placebo-controlled trial with nosocomial infection as the primary outcome variable is planned once dose-finding is complete. This study is being conducted by the NICHD's Collaborative Pediatric Critical Care Research Network (CPCCRN) with Nationwide Children's Hospital as the primary site. The study design information currently displayed on this site refers to the dose-finding phase of the project.

Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Admission to the PICU at a CPCCRN site with a primary diagnosis of blunt or penetrating trauma that occurred within the last 72 hours.
  • Age 1 - 17 years
  • Provisional Injury Severity Score (ISS) > 10
  • Presence of an endotracheal tube at the time of enrollment

Exclusion Criteria:

  • DNR status or care team/family is considering plans for withdrawal of life-sustaining therapies.
  • Strong suspicion of injuries related to child abuse, in the opinion of the treating physician
  • Persistence (after treatment) of any of the following in the PICU before enrollment: Fixed, dilated pupils; Glasgow Coma Scale score of 3 (in the absence of neuromuscular blocking drugs); or presence of a new, severe neurologic injury at the time of enrollment which, in the opinion of the treating physician, is highly likely to lead to a diagnosis of brain death
  • Cardiopulmonary arrest requiring CPR documented by EMS or hospital personnel prior to subject identification
  • Burn injury of any kind (scald, fire, chemical)
  • Patients receiving acute or chronic immunosuppressive therapy (e.g., systemic corticosteroids, calcineurin inhibitors, mycophenolate, azathioprine) at the time of injury
  • Patients with severe leukopenia (white blood cell count < 1000 cells/mm3) at the time of injury as the result of myeloablative chemotherapy or radiation
  • Pregnancy
  • Autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells, or known allergy/hypersensitivity to GM-CSF
  • Previously enrolled in the GIFT study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01495637

Contact: Mark W Hall, MD 614-722-3438

United States, Colorado
Children's Hospital of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Peter Mourani, MD    720-777-1234      
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Murray Pollack, MD    202-476-5000      
United States, Michigan
Children's Hospital of Michigan Recruiting
Detroit, Michigan, United States, 48201
Contact: Kathleen Meert, MD    313-745-5437      
United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Mark W Hall, MD    614-722-3438   
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Athena Zuppa, MD    800-879-2467      
Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Joseph A Carcillo, MD    412-692-5325      
Sponsors and Collaborators
Mark Hall
National Institute of General Medical Sciences (NIGMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Mark W Hall, MD Nationwide Children's Hospital
  More Information

Responsible Party: Mark Hall, Associate Professor of Pediatrics, Nationwide Children's Hospital Identifier: NCT01495637     History of Changes
Other Study ID Numbers: GIFT Study
R01GM094203 ( US NIH Grant/Contract Award Number )
Study First Received: December 13, 2011
Last Updated: May 4, 2016
Individual Participant Data  
Plan to Share IPD: Yes

Keywords provided by Mark Hall, Nationwide Children's Hospital:

Additional relevant MeSH terms:
Wounds and Injuries processed this record on May 25, 2017